Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vir Biotechnology Q4 2023 GAAP EPS $(0.86) Beats $(1.00) Estimate, Sales $16.79M Beat $12.15M Estimate

Author: Benzinga Newsdesk | February 22, 2024 05:36pm
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.00) by 14 percent. The company reported quarterly sales of $16.79 million which beat the analyst consensus estimate of $12.15 million by 38.11 percent. This is a 66.03 percent decrease over sales of $49.41 million the same period last year.

Posted In: VIR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist